Roche drops Carmot’s acmopatide after Phase 2 success, shifts focus to enicepatide for weight loss and diabetes

Roche announced it will stop developing acmopatide, an investigational obesity treatment acquired from Carmot Therapeutics.

Acmopatide had met its primary endpoint in a Phase 2 trial in type 1 diabetes, showing a 0.34% reduction in A1C at a 4.1‑mg dose and 56% of patients achieving A1C below 7% versus placebo.

The company said the decision reflects a strategic shift to prioritize enicepatide, another Carmot candidate, for weight‑loss, type 2 diabetes and cardiovascular outcomes.

The move was disclosed in an investor presentation accompanying Roche’s second‑quarter earnings report, underscoring the firm’s focus on assets with broader market potential.